Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ADR Biomedical HoldingsTSE:3750 -0.65%24 Days Payable is 22.53 as of Mar. 2026, which is 374% above its 10-year median of 4.75. GuruFocus rates TSE:3750 with a GF Score™ of 24/100 and a GF Value™ of 円39.23 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 704 Biotechnology companies, ADR Biomedical Holdings ranks better than 55.26% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:3750 vs VRTX, REGN, RVMD: Days Payable Comparison
For the Biotechnology subindustry, ADR Biomedical Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADR Biomedical Holdings Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADR Biomedical Holdings's Days Payable distribution charts can be found below:
* The bar in red indicates where ADR Biomedical Holdings's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
ADR Biomedical Holdings's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADR Biomedical Holdings (TSE:3750) has a Days Payable of 22.53 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ADR Biomedical Holdings and its competitors. This is 374% above median its historical median of 4.75. Over the past decade, ADR Biomedical Holdings' Days Payable has ranged from 0.79 to 138.75. According to the industry distribution chart, ADR Biomedical Holdings ranks #315 out of 704 companies in the Biotechnology industry, placing it in the top 44.7%.
Is ADR Biomedical Holdings' Days Payable too high?
ADR Biomedical Holdings' current Days Payable of 22.53 is 374% above median its 10-year median of 4.75. Over the past 10 years, this metric has ranged from a low of 0.79 to a high of 138.75. The Biotechnology industry median Days Payable is 110.01. ADR Biomedical Holdings' value of 22.53 is 79.5% below this industry median. Based on the distribution chart, ADR Biomedical Holdings ranks #315 out of 704 companies in the Biotechnology industry, which is above the industry midpoint. Overall, ADR Biomedical Holdings has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ADR Biomedical Holdings' Days Payable compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ADR Biomedical Holdings ranks #315 out of 704 companies for Days Payable. This puts ADR Biomedical Holdings in the upper half of its industry. The industry median Days Payable is 110.01. ADR Biomedical Holdings' value of 22.53 is 79.5% below this benchmark. Historically, ADR Biomedical Holdings' own Days Payable has ranged from 0.79 to 138.75 over the past decade. While the company's 10-year median is 4.75 vs. the industry median of 110.01, ADR Biomedical Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 110.01, based on 704 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADR Biomedical Holdings's current Days Payable of 22.53 is 79.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on ADR Biomedical Holdings and its competitors. For the Biotechnology industry, the median Days Payable is 110.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADR Biomedical Holdings's current Days Payable is 22.53, which is 374% above median its own 10-year median of 4.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADR Biomedical Holdings stock overvalued right now?
Based on GuruFocus' analysis, ADR Biomedical Holdings (TSE:3750) is currently considered Significantly Overvalued. The stock's GF Value™ is 円39.23, compared to a current price of 円764.00 — trading 1847.5% above its estimated fair value. The current Days Payable is 22.53, which is 374% above median its 10-year median of 4.75 and 79.5% below the Biotechnology industry median of 110.01. ADR Biomedical Holdings' overall GF Score™ is 24/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For ADR Biomedical Holdings (TSE:3750), the current Days Payable is 22.53 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADR Biomedical Holdings (TSE:3750) Overvalued in 2026?
Based on GuruFocus' analysis, ADR Biomedical Holdings stock appears to be overvalued.
The current stock price of 円764.00 is trading 1847.5% above its estimated GF Value™ of 円39.23.
GuruFocus considers ADR Biomedical Holdings to be Significantly Overvalued.
Key valuation signals for TSE:3750:
Days Payable: 22.53 (374% above median its 10-year median of 4.75)
GF Value™: 円39.23 vs. price of 円764.00 (1847.5% above fair value)
Industry Position: 79.5% below the Biotechnology median (#315 of 704)
No single metric tells the full story. See the TSE:3750 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADR120S Inc developing a new clinical approach to cell therapy to provide medical care to patients by providing medical care that responds to unmet medical needs based on its regenerative medicine. Its product pipeline includes Habeo; ECCO-50 and others.
24GF Score
Get the complete analysis for TSE:3750
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3750 has been successfully added to your 
